Jerena Manoharan1, Friedhelm Raue2, Caroline L Lopez3, Max B Albers3, Carmen Bollmann3, Volker Fendrich3, Emily P Slater3, Detlef K Bartsch3. 1. Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany. jerena.manoharan@uk-gm.de. 2. Practice and Molecular Laboratory, Brueckenstrasse 21, 69120, Heidelberg, Germany. 3. Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Abstract
BACKGROUND: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years. The occurrence of clinically relevant MEN1 organ manifestations in children (≤18 years) was evaluated. METHODS: Two prospective collected databases of MEN1 patients (n = 166) who underwent annual screening were retrospectively analyzed for organ manifestations in MEN1 patients ≤18 years. The follow-up was based on the most recent screening examination until December 2015. RESULTS: Twenty [11 females, 9 males, (12%)] of 166 MEN1 patients were diagnosed with at least one organ manifestation at age ≤18 years. The most frequent manifestation was mild asymptomatic pHPT (n = 9, 45%, age range 8-18 years). Eight (40%) young patients had pNENs (three non-functioning pNENs, five insulinomas, age range 9-18 years). All five insulinomas were diagnosed based on hypoglycemic symptoms. The other organ manifestations were asymptomatic pituitary adenomas in six patients (30%, age range 15-18 years) and a bronchial carcinoid in one 15-year-old patient. Only six (30%) patients ≤18 years had clinically relevant organ manifestations. CONCLUSION: Symptomatic or severe manifestations in MEN1 patients rarely occur below the age of 16 years. With regard to psychological burden and cost-effectiveness, routine screening of asymptomatic MEN1 patients should be postponed at least until the age of 16 years.
BACKGROUND: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years. The occurrence of clinically relevant MEN1 organ manifestations in children (≤18 years) was evaluated. METHODS: Two prospective collected databases of MEN1patients (n = 166) who underwent annual screening were retrospectively analyzed for organ manifestations in MEN1patients ≤18 years. The follow-up was based on the most recent screening examination until December 2015. RESULTS: Twenty [11 females, 9 males, (12%)] of 166 MEN1patients were diagnosed with at least one organ manifestation at age ≤18 years. The most frequent manifestation was mild asymptomatic pHPT (n = 9, 45%, age range 8-18 years). Eight (40%) young patients had pNENs (three non-functioning pNENs, five insulinomas, age range 9-18 years). All five insulinomas were diagnosed based on hypoglycemic symptoms. The other organ manifestations were asymptomatic pituitary adenomas in six patients (30%, age range 15-18 years) and a bronchial carcinoid in one 15-year-old patient. Only six (30%) patients ≤18 years had clinically relevant organ manifestations. CONCLUSION: Symptomatic or severe manifestations in MEN1patients rarely occur below the age of 16 years. With regard to psychological burden and cost-effectiveness, routine screening of asymptomatic MEN1patients should be postponed at least until the age of 16 years.
Authors: Nina Strømsvik; Karin Nordin; Gunilla Berglund; Lars F Engebretsen; Mats G Hansson; Eva Gjengedal Journal: J Genet Couns Date: 2007-02-03 Impact factor: 2.537
Authors: B Gatta-Cherifi; O Chabre; A Murat; P Niccoli; C Cardot-Bauters; V Rohmer; J Young; B Delemer; H Du Boullay; M F Verger; J M Kuhn; J L Sadoul; Ph Ruszniewski; A Beckers; M Monsaingeon; E Baudin; P Goudet; A Tabarin Journal: Eur J Endocrinol Date: 2011-11-14 Impact factor: 6.664
Authors: P Goudet; A Dalac; M Le Bras; C Cardot-Bauters; P Niccoli; N Lévy-Bohbot; H du Boullay; X Bertagna; P Ruszniewski; F Borson-Chazot; B Vergès; J L Sadoul; F Ménégaux; A Tabarin; J M Kühn; P d'Anella; O Chabre; S Christin-Maitre; G Cadiot; C Binquet; B Delemer Journal: J Clin Endocrinol Metab Date: 2015-01-16 Impact factor: 5.958
Authors: Jens Waldmann; Volker Fendrich; Nils Habbe; Detlef K Bartsch; Emily P Slater; Peter H Kann; Matthias Rothmund; Peter Langer Journal: World J Surg Date: 2009-06 Impact factor: 3.352
Authors: S Schaefer; M Shipotko; S Meyer; D Ivan; K J Klose; J Waldmann; P Langer; P H Kann Journal: Eur J Endocrinol Date: 2008-05 Impact factor: 6.664